Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 183

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 183
---
 party on the date of the Kineta Merger Agreement and on the closing date and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the Kineta Merger Agreement. No assurance can be given that the required stockholder approvals will be obtained or that the required conditions to closing will be satisfied (including the condition to complete a financing transaction), and, if all required consents and approvals are obtained and such conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the Kineta Merger could cause some or all of the benefits that we expect to achieve if the Kineta Merger is successfully completed within its expected time frame not to be realized, or to be delayed in realizing.

We need to obtain financing in connection with the Kineta Merger and cannot guarantee that we will be able to complete such financing. 

Our ability to complete the contemplated Concurrent Investment will depend on, among other factors, prevailing market conditions and other factors beyond our control. We cannot provide assurance that we will be able to obtain financing on terms acceptable to it or at all, and any such failure could materially adversely affect our operations and financial condition. Our obligation to complete the Kineta Merger is conditioned upon the receipt of the Concurrent Investment. In the event such capital raise is the only condition to the closing of the Kineta Merger not otherwise satisfied, we have agreed to make a $1 million termination fee payment to Kineta if the Kineta Merger Agreement is terminated in accordance with its terms. 

We will incur significant transaction and Kineta Merger-related transition costs in connection with the Kineta Merger. 

We expect that we will incur significant, non-recurring costs in connection with consummating the Kineta Merger and integrating the operations of the two companies post-closing. We may incur additional costs to retain key employees. We will also incur significant fees and expenses relating to financing arrangements and legal services (including any costs that would be incurred in defending against any potential class action lawsuits and derivative lawsuits in connection with the Kineta Merger if any such proceedings are brought), accounting and other fees and costs, associated with consummating the Kineta Merger. Some of these costs are payable regardless of whether the Kineta Merger is completed. In addition, we may be required to pay a termination fee of $1,000,000 if the Kineta Merger Agreement is terminated under